Atrium-targeted drug delivery through an amiodarone-eluting bilayered patch  by Bolderman, Robert W. et al.
E
T
/B
S
Evolving Technology/Basic Science Bolderman et alAtrium-targeted drug delivery through an amiodarone-eluting
bilayered patchRobert W. Bolderman, MD,a Peter Bruin, PhD,c J. J. Rob Hermans, PhD,b Mark J. Boerakker, PhD,c
Aylvin A. Dias, PhD,c Frederik H. van der Veen, PhD,a and Jos G. Maessen, MD, PhDaFrom th
Resea
Gelee
Support
effort
DSM
ical C
Disclosu
Receive
public
Address
Maas
Box
unima
0022-52
Copyrig
doi:10.1
904Objective:Clinical studies have demonstrated the efficacy of oral and intravenous amiodarone therapy to prevent
postoperative atrial fibrillation. However, because of significant extracardiac side effects, only high-risk patients
are eligible for prophylactic amiodarone therapy. This study addressed the hypothesis that atrium-specific drug
delivery through an amiodarone-eluting epicardial patch reduces vulnerability to atrial tachyarrhythmias, whereas
ventricular and plasma drug concentrations are minimized.
Methods: Right atrial epicardiums of goats were fitted with electrodes and a bilayered patch (poly[ethylene gly-
col]–based matrix and poly[lactide-co-caprolactone] backing layer) loaded with amiodarone (10 mg per patch,
n ¼ 10) or without drug (n ¼ 6). Electrophysiologic parameters (atrial effective refractory period, conduction
time, and rapid atrial response to burst pacing) and amiodarone levels in plasma and tissue were measured during
1 month’s follow-up.
Results: Epicardial application of amiodarone-eluting patches produced persistently higher drug concentrations
in the right atrium than in the left atrium, ventricles, and extracardiac tissues by 2 to 4 orders of magnitude. Atrial
effective refractory period and conduction time increased, whereas rapid atrial response inducibility decreased
significantly (P< .05) during the 1-month follow-up compared with that seen in animals treated with drug-
free patches. Amiodarone concentrations in plasma remained undetectably low (<10 ng/mL).
Conclusions: Atrium-specific drug delivery through an amiodarone-eluting patch produces therapeutic atrial
drug concentrations, whereas ventricular and systemic drug levels are minimized. This study demonstrates that
sustained targeted drug delivery to a specific heart chamber is feasible and might reduce the risk for ventricular
and extracardiac adverse effects. Epicardial application of amiodarone-eluting patches is a promising strategy to
prevent postoperative atrial fibrillation. (J Thorac Cardiovasc Surg 2010;140:904-10)Postoperative atrial fibrillation (POAF) is the most frequent
complication of cardiac surgery, with incidence rates vary-
ing between 20% and 60% depending on the type of proce-
dure and the criteria for diagnosis.1 POAF is associated with
an increased risk of morbidity and mortality caused by
stroke, heart failure, ventricular arrhythmias, thromboembo-
lism, and bleeding from anticoagulation.2 Furthermore,
POAF increases length of hospital stay, hospital readmission
rate, and hospital costs.
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The Journal of Thoracic and Cardiovascular Surg2006 joint guidelines, POAF should be prevented by treat-
ment with an oral b-blocker or, in patients are at high risk,
preoperative administration of amiodarone.3 Although
amiodarone is probably the most effective drug, it is
reserved as a second-line agent because of its associated
risk of potentially severe extracardiac adverse effects, such
as thyroid dysfunction, pulmonary toxicity, and hepatic tox-
icity.4 These effects are in part attributable to the relatively
high drug concentrations required with systemic administra-
tion. Another disadvantage of amiodarone is the need for
a loading period.5
Local drug delivery could minimize the ventricular and
extracardiac adverse effects of amiodarone and could make
a loading period superfluous. Several studies investigated
intrapericardial infusion of amiodarone solutions to achieve
local drug delivery.6-8 However, this method does not allow
for atrium-specific drug targeting because the drug equally
diffuses to the ventricular epicardium. Epicardial application
of drug-releasing biomaterials might offer the advantage of
a more localized (heart chamber–targeted) drug delivery,
although diffusion to other heart chambers, partly through
leakage to the pericardial fluid, is still possible.9
We reasoned that atrium-specific amiodarone therapy
might be achieved if a bilayered patch would be applied
epicardially in such a way that an amiodarone-loaded matrixery c October 2010
Abbreviations and Acronyms
ECG ¼ electrocardiography
ERP ¼ effective refractory period
LA ¼ left atrium
LV ¼ left ventricle
PEG ¼ poly(ethylene glycol)
PLCL ¼ poly(lactide-co-caprolactone)
POAF ¼ postoperative atrial fibrillation
RA ¼ right atrium
RAR ¼ rapid atrial response
RV ¼ right ventricle
Bolderman et al Evolving Technology/Basic Sciencefaces the epicardium and an impermeable backing layer
faces the pericardium. This study addressed the hypothesis
that amiodarone-eluting bilayered patches reduce vulnera-
bility to atrial tachyarrhythmias in chronically instrumented
goats while ventricular and systemic drug concentrations are
minimized.E
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All procedures were approved by the Animal Studies Committee of the
University of Maastricht and performed according to the principles of ‘‘The
guide for the care and use of laboratory animals’’ published by the National
Institutes of Health (National Institutes of Health publication no. 85-23,
revised 1996).
Domestic goats (n ¼ 16; weight, 47–67 kg) were randomly assigned to
a drug-free patch group (DFP group, n ¼ 6) or an amiodarone-loaded patch
group (ALP group, n¼ 10). Four animals of the ALP group were only used
for pharmacokinetic studies, whereas all other animals were chronically
instrumented with epicardial electrodes.
Patch Synthesis
Preparation of poly(ethylene glycol) 10,000 tetra(4-
pentenoate). Under a nitrogen atmosphere, 20 g of poly(ethylene gly-
col) (PEG) 10,000 4-arm hydroxyl (Nektar Therapeutics, San Carlos, Calif)
was dissolved in 200 mL of toluene and 50 mL of dichloromethane and
cooled with an ice bath. Triethylamine (2.8 mL) was added to the clear
solution. Then 2.4 mL of 4-pentenoylchloride (Sigma-Aldrich, St Louis,
Mo) was added dropwise to the ice-cooled solution. The reaction was con-
tinued overnight at room temperature. Triethylamine salts were then filtered
off in vacuo, and the clear filtrate was precipitated into 2 L of ice-cold dieth-
ylether. The solid precipitate was collected and redissolved in 100 mL of
chloroform. This solution was reprecipitated into excess of hexane. The pre-
cipitate was collected and dried in vacuo. This yielded approximately 15 g
(97.8%) of star-shaped PEG 10,000 tetra(4-pentenoate) as a white powder.
The polymer was characterized by using 1H-nuclear magnetic resonance
spectroscopy (at 300 MHz, 22C with deuterated chloroform as a solvent
and tetramethylsilane as an internal standard): d (ppm) ¼ 5.79 (m, 4H,
CH¼CH2); 5.05 (m, 8H,CH¼CH2); 4.22 (t, 8H,OCH2CH2O[C¼O]);
and 3.89 to 3.35 (m, 938H,OCH2CH2O[C¼O] and[OCH2CH2]nO)
and C(CH2O)4.
Fabrication of bilayered patches. Two grams of PEG 10,000
tetra(4-pentenoate) and 0.1 g adipic thioic acid (1,6-hexane dithioic acid)
were dissolved in 2 mL of tetrahydrofuran.10 Photoinitiator Darocur 1173
(0.05 g; Ciba, Basel, Switzerland) and 10% wt/wt (relative to PEG plus
cross-linker) amiodarone powder (Sigma-Aldrich) were added to this solu-The Journal of Thoracic and Cation. The suspension was stirred vigorously and transferred into circular
Teflon molds (14-mm diameter) on top of a 50-mm-thick elastic film com-
posed of a poly(lactide-co-caprolactone) (PLCL) copolymer. The suspen-
sions were exposed to UV light (5x1 J/cm2) and dried in vacuo for
several days, resulting in the formation of biodegradable bilayered discoidal
patches composed of a amiodarone-loaded PEGmatrix and a PLCL backing
layer. Patches were 300 mm thick, had a diameter of 13 mm, weighed
101  4 mg, and contained 9.9  0.4 mg of amiodarone. The amiodarone
dose was selected based on pilot experiments, which demonstrated an
increase in atrial effective refractory periods (ERPs) 28 days after patch
application. Drug-free patches were synthesized according to the same
procedure without the addition of amiodarone.
Patch Application
Goats were anesthetized with isoflurane (2% to 3%) with a 1:1 mixture
of oxygen and air after induction of anesthesia with thiopental, 20 mg/kg
administered intravenously. During surgical intervention, limb-lead electro-
cardiography (ECG), arterial blood pressure, temperature, end-expiratory
CO2, and oxygen saturation (pulse oximetry) were monitored. Saline
(0.9%, 5–8 mL/kg per hour) was infused through a peripheral venous cath-
eter. Buprenorphine (10 mg/kg administered intravenously) was used as an
analgesic.
A right intercostal thoracotomywas performed, and the right atrial lateral
wall was exposed. In goats scheduled for chronic electrophysiologic studies,
2 silicone strips of 103 10 mm, each containing 4 silver unipolar electrodes
(1.5-mm diameter and 5-mm interelectrode distance), were sutured to the
right atrial lateral wall, one close to the superior caval vein and the other
close to the inferior caval vein. After baseline measurements, a patch
(loaded with or without amiodarone) was sutured to the right atrial lateral
wall (between the 2 electrode-containing silicone strips), and electrophysi-
ologic measurements were repeated after 1 hour. The pericardium and
thorax were subsequently closed, and the electrode leads were tunneled
subcutaneously to the neck and exteriorized. Animals were injected with
prophylactic ampicillin (20 mg/kg administered intramuscularly) before
and directly after surgical intervention. Buprenorphine (10 mg/kg adminis-
tered intramuscularly twice daily) was administered postoperatively for
3 days.
Electrophysiologic Studies
Electrophysiologic parameters were measured during surgical interven-
tion and at days 1, 2, 3, 4, 7, 9, 11, 14, 16, 18, 21, 23, 25, and 28 after
surgical intervention. ECG limb leads and electrodes were connected to
an electrophysiologic monitoring system with an integrated amplifier/stim-
ulator (EP-Tracer 38; CardioTek, Maastricht-Airport, The Netherlands).
From the ECG results obtained during sinus rhythm, R-R, PQ, QT, and
maximal Tpeak-Tend intervals and P and QRS widths were measured. Four
bipolar electrograms were recorded simultaneously from the 2 silicone
strips flanking the patch.
For measurement of atrial ERP, 10 basic stimuli (S1, 400-ms interval)
were applied by means of bipolar pacing at 4 times the threshold. After
S1, an extra stimulus (S2) was applied starting from well within the refrac-
tory period. The S1–S2 interval was increased with 2-ms steps, and atrial
ERP was defined as the longest S1–S2 interval that failed to capture.
For measurement of conduction times, the atrium was paced (400-ms in-
terval) at the silicone strip close to the superior caval vein. Conduction time
was defined as the time between stimulus artifact and corresponding atrial
deflection of the electrogram recorded at the silicone patch close to the
inferior caval vein, representing the conduction delay across the crista termi-
nalis.
Inducibility of a rapid atrial response (RAR) was measured by applying
50-Hz burst pacing during 1 second. If the burst stimulus produced a rapid
irregular rhythm lastingmore than 1 second, RARwas considered inducible.
RAR inducibility was quantified by the percentage of RAR inductions after
20 attempts, and median RAR episode durations were calculated.rdiovascular Surgery c Volume 140, Number 4 905
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Blood samples were regularly drawn from a peripheral vein of the hind
limb through a Venflon cannula (Becton Dickinson, Franklin Lakes, NJ) up
to 28 days after patch application. The blood was collected in ethylenedi-
amine tetraacetic acid–containing Vacutainer tubes (Becton Dickinson)
and centrifuged to obtain plasma that was stored at80C. At 3 hours and
1, 7, 14, 21, and 28 days after patch application, goats of the ALP group
(n ¼ 1 for each time point) were killed with intravenous sodium pentobar-
bital, and the heart was excised. The lateral right atrium (RA) and free-wall
sections (4 cm2) of the left atrium (LA) and both ventricles were dissected.
In addition, samples of pericardium overlying the RA, pericardial fluid, the
medial part of the cranial lobe of the right lung, skeletal muscle of the hind
limb, and liver and abdominal fat were obtained. After immersion in liquid
nitrogen for rapid freezing, tissue samples were stored at80C. For mea-
surement of transmural drug concentration gradients, myocardial samples
were freeze-microtomed parallel to the epicardial surface in slices of 500
mm. High-performance liquid chromatography coupled with UV detection
was used to determine amiodarone and desethylamiodarone concentrations
in plasma, pericardial fluid, and tissue samples.11
Statistics
Data are expressed as means standard deviations. Differences between
means were calculated with a Kruskal–Wallis test for multiple comparisons.
To determine the significance of differences of individual comparisons,
Mann–Whitney U and Wilcoxon signed rank tests were used for
between-group and within-group comparisons, respectively, with post hoc
Bonferroni correction.
RESULTS
Feasibility and Tolerability of Patch Application
After baseline measurements, suturing of patches to the
atria was achieved within 5 minutes in each animal, without
significant bleeding or changes in blood pressure. Hemody-
namic and ECG parameters remained stable during the
remainder of the surgical procedures. No signs of discom-
fort, adverse effects, or complications were observed up to
28 days after patch application. Except for a 70-ms longer
R-R interval in the ALP group than in the DFP group atTABLE 1. ECG parameters
T
0 1 3
R-R interval (ms) ALP 463  46 473  44 509 
DFP 435  55 452  51 439 
P width (ms) ALP 64  7 68  6 68 
DFP 62  6 62  7 64 
PQ interval (ms) ALP 109  9 111  10 124 
DFP 106  13 107  12 113 
QRS width (ms) ALP 62  6 64  6 63 
DFP 62  5 62  4 62 
QT interval (ms) ALP 277  16 279  18 282 
DFP 271  22 274  26 262 
Tpeak-Tend (ms) ALP 35  4 36  6 37 
DFP 33  4 34  5 33 
Presented data were obtained from electrocardiographic recordings during normal sinus
amiodarone-loaded patch (ALP) and drug-free patch (DFP) groups. *P< .05, ALP versus
906 The Journal of Thoracic and Cardiovascular Surgday 3 after patch application, ECG parameters did not signif-
icantly differ between groups over the time period evaluated
in the present study (Table 1). Gradual prolongations of R-R
intervals observed in both groups during follow-up can be
explained by animal habituation because similar ECG
changes were observed in animals in which no patch was
applied (data not shown). In all animals killed after 7 or
more days, electrode strips and patches were covered by
a thin (<1 mm) fibrous layer, without signs of pericarditis
or myocarditis.
Pharmacokinetic Feasibility of Atrium-Targeted
Drug Delivery
Epicardial application of amiodarone-eluting patches
produced persistently higher drug concentrations in the
RA than in the LA, right ventricle (RV), and left ventricle
(LV; Figure 1). RA/LA, RA/RV, and RA/LV mean amio-
darone concentration ratios at 3 hours after patch application
were 40, 67, and 76, respectively. These ratios increased to
1145, 2247, and 2167, respectively, at 28 days after patch
application. Amiodarone concentrations reached peaks after
24 hours of patch application in all tissues studied. Cardiac
tissue concentrations decreased in the next 27 days, with
overall half-lives of 4 to 5 days (assuming monoexponential
decrease). Peak amiodarone concentrations in extracardiac
tissues were 3 to 4 orders of magnitude lower than right atrial
peak drug concentrations and decreased to less than 10 ng/
mL (detection limit) at 21 days after patch application. For
all blood samples drawn during the 28-day follow-up period,
plasma amiodarone levels were less than the detection limit.
Because amiodarone has a high tissue affinity, lower drug
levels in plasma than in tissues are expected. These findings
are also in line with the lower drug levels measured in peri-
cardial fluid than in pericardial tissue (Figure 1, C).ime after patch application (d)
7 14 21 28
47* 546  51 616  84 656  82 672  83
47 488  58 565  56 626  66 648  70
7 71  6 73  5 74  5 76  5
5 66  7 69  5 72  4 73  6
11 136  15 140  10 140  8 139  9
14 126  15 132  10 135  14 136  10
4 63  5 62  6 62  6 62  6
4 62  4 63  5 64  5 63  5
20 290  19 309  22 316  20 325  28
20 273  17 298  19 313  25 322  29
4 40  5 42  6 44  6 47  4
5 37  6 40  7 44  8 46  8
rhythm. Values are presented as means  standard deviations. n ¼ 6 for both the
DFP.
ery c October 2010
FIGURE 1. Amiodarone distribution. A, Epicardial amiodarone concentrations in the right atrium (RA), left atrium (LA), right ventricle (RV), and left ven-
tricle (LV). B, Endocardial amiodarone concentrations in the RA, LA, RV, and LV. C, Amiodarone concentrations in pericardium and pericardial fluid. D,
Amiodarone concentrations in abdominal fat, the medial part of the cranial lobe of the right lung, skeletal muscle of the hind limb, and the liver. Data were
obtained 3 hours and 1, 7, 14, 21, and 28 days after patch application. n ¼ 1 for each time point. *Amiodarone concentration less than the detection limit
(<10 ng/mL).
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lamiodarone. Desethylamiodarone levels in the RA were 3
orders of magnitude lower than amiodarone levels, whereas
metabolite concentrations in the other heart chambers were
1 order of magnitude lower than parent drug concentrations
(data not shown). Distribution of desethylamiodarone in
extracardiac tissues was similar to amiodarone distribution.
Plasma metabolite levels remained undetectably low during
the 28-day follow-up period.
Pharmacodynamic Feasibility: Antiarrhythmic
Efficacy
Effects of patch application on atrial electrophysiology
are shown in Figure 2. Application of amiodarone-loaded
patches produced significant increases in right atrial ERPs
and conduction times over the time period evaluated in the
present study. The ERP in the ALP group was maximal at
192  19 ms at 3 days after patch application compared
with 163  10 ms in the DFP group. At 28 days after patch
application, the ERP was still 20 ms higher in the ALP
group. With respect to conduction times, no significant dif-
ferences between groups were observed during baseline
measurements. After application of amiodarone-loaded
patches, conduction times tended to prolong, with mean
changes ranging fromþ1.3% toþ10.5%, whereas a shorten-
ing was observed after application of drug-free patches, with
mean changes ranging from5.0% to11.7%, producingThe Journal of Thoracic and Casignificant differences between the ALP and DFP groups
(except for day 2 after patch application).
Atrial burst pacing in both groups did not produce
sustained (ie,>60 seconds) episodes of atrial fibrillation
either at baseline measurements or follow-up. Instead,
RARs, typically lasting several seconds, were observed
(Figure 3). RAR inducibility was significantly decreased in
the ALP group compared with that seen in the DFP group
from days 2 to 28 after patch application (Figure 2, C).
Durations of RAR episodes tended to be longer in the
DFP group, but this only reached significance in the
2 days after application of drug-free patches and during
the last 2 weeks of follow-up (Figure 2, D).
DISCUSSION
The main findings of this study are that epicardial applica-
tion of bilayered amiodarone-eluting patches (1) is well
tolerated, (2) yields persistently higher drug concentrations
in the RA than in other cardiac and extracardiac tissues
(by 2–4 orders of magnitude), (3) increases ERPs and con-
duction times, and (4) decreases vulnerability to burst pac-
ing–induced atrial tachyarrhythmias for at least 28 days.
Two decades ago, lidocaine-releasing polyurethane matri-
ceswere studied for the treatment of ventricular fibrillation.12
The aim of developing these drug-delivery systems was to
achieve sustained therapeutic myocardial concentrations at
reduced systemic drug concentrations, minimizing the riskrdiovascular Surgery c Volume 140, Number 4 907
FIGURE 2. Atrial electrophysiology. A, Effective refractory period. B, Change in conduction time relative to baseline measurements. C, Rapid atrial re-
sponse (RAR) inducibility. D, Median RAR duration. n ¼ 6 for both the amiodarone-loaded patch (ALP) and drug-free patch (DFP) groups. *P< .05.
Evolving Technology/Basic Science Bolderman et al
E
T
/B
Sfor unwanted extracardiac effects. Polyurethane matrices
were subsequently loaded with propanolol, verapamil, and
ibutilide, all demonstrating successful local drug delivery
for several hours in animal studies.13-15 However,
polyurethane is nonbiodegradable, which limits its clinical
use as a matrix for epicardial drug delivery. One study
investigated the long-term effects of sotalol controlled-
release implants, including polyurethane and silicone matri-
ces applied to the ventricular epicardium and intrapericar-
dially infused biodegradable poly(lactic-co-glycolic acid)
microspheres.9 Thirty days after poly(lactic-co-glycolic
acid) microsphere delivery, atrial drug concentrations were
similar to ventricular drug concentrations, whereas 60 days
after silicone matrix application, sotalol levels between
matrix-covered and noncovered ventricular myocardium
were equal. These results indicate that the use of drug deliv-
ery systems that only consist of drug-loaded matrices do not
allow targeting of one specific myocardial region. The most
likely mechanism is drug release from the matrix into the
pericardial fluid, which facilitates rapid drug distribution to
other heart chambers. However, other transport mechanisms
(eg, through subepicardial lymphatics or vascular plexi)
might also contribute to pan–cardiac drug distribution.
In the present study a biodegradable bilayered patch was
used, consisting of an amiodarone-loaded matrix facing the
epicardium and an impermeable backing layer facing the
pericardium. The latter minimizes drug release into the peri-
cardial fluid, thereby slowing distribution to other cardiac
regions and enabling longer-lasting site-specific drug deliv-
ery. Indeed, this seems to be reflected by the very high amio-908 The Journal of Thoracic and Cardiovascular Surgdarone concentrations in the epicardium of the RA compared
with epicardial levels in other heart chambers up to 28 days
after patch application. Regarding endocardial amiodarone
concentrations, which were lower than epicardial drug con-
centrations, these regional differences appeared to be some-
what smaller, probably because of drug distribution through
the lymphatics and blood vessels, different diffusion charac-
teristics of the cardiac tissue layers, or both. After burst
release in the first 24 hours after application, patches yielded
monoexponentially decreasing amiodarone concentrations
over the next 4 weeks. Epicardially applied PEG-based ma-
trices with thioester bonds degrade within several weeks, in-
dicating that the monoexponential decrease of drug levels
was probably both diffusion and degradation mediated.16
A PLCL matrix was selected as the backing layer because
this copolymer degrades much slower, on the order of 6 to
12 months, ensuring preserved impermeability during amio-
darone release from the PEG-based matrix.17
Previous studies used the pericardial sac as a drug reser-
voir to achieve local amiodarone delivery for several hours.
Intrapericardial infusion in dogs resulted in high tissue amio-
darone concentrations in atria and the ventricular epicar-
dium, whereas plasma only contained trace drug
concentrations.6 In addition, atrial vulnerability to electri-
cally induced tachyarrhythmias was decreased. In pigs it
was shown that the higher atrial uptake of amiodarone, in
contrast to epicardial ventricular uptake, was positively
related to the intrapericardially delivered dose.7 In a recent
study in goats, we observed transmural amiodarone concen-
tration gradients with high epicardial drug levels in both atriaery c October 2010
FIGURE 3. Typical responses to burst pacing 28 days after patch applica-
tion. ECG, Electrocardiography;BIP RA, right atrial bipolar electrode; RAR,
rapid atrial response.
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similar epicardial and endocardial antiarrhythmic efficacy.8
Intravenous infusion of an equal amiodarone dose resulted
in significantly lower antiarrhythmic efficacy both epicar-
dially and endocardially. The present study demonstrates
atrium-specific amiodarone delivery during a much longer
period than seen in previous intrapericardial infusion stud-
ies. Amiodarone-loaded patches produced significant antiar-
rhythmic effects up to 28 days after application, whereas
plasma drug levels remained less than 10 ng/mL (detection
limit), which is more than 100 times lower than therapeutic
plasma levels during intravenous or chronic oral amiodarone
administration. Peak amiodarone concentrations in extracar-
diac tissues, such as fat, lung, skeletal muscle, and liver,
were 2 to 4 orders of magnitude lower than levels observed
during long-term oral amiodarone therapy.18
Amiodarone has multiple electrophysiologic effects, in-
cluding class I, II, III, and IV antiarrhythmic actions.19
In the present study atrial ERPs were maximally prolonged
in the first days after patch application, whereas effects on
conduction times were maximal 2 weeks later, despite de-
creasing atrial amiodarone concentrations. The latter can
be explained by treatment duration–dependent changes inThe Journal of Thoracic and Caamiodarone’s ionic current blocking profile or by postoper-
ative factors simultaneously affecting conduction time. The
presence of surgical intervention–related influences on atrial
electrophysiology was apparent in animals treated with
drug-free patches, showing a peak of atrial arrhythmic vul-
nerability on days 2 and 3 after thoracotomy, which coin-
cides with the peak incidence of POAF.20 Treatment with
amiodarone-loaded patches significantly attenuated atrial
vulnerability to burst pacing–induced tachyarrhythmias.
Therefore efficacy of this new technique in preventing
POAF is anticipated. QT intervals and maximal Tpeak-Tend
intervals did not differ between the ALP and DFP groups,
indicating low risk of drug-induced ventricular arrhythmias.
In addition to POAF, epicardial polymeric release systems
have also been investigated for other clinical applications, re-
quiring delivery of substanceswith a highermolecularweight
than amiodarone. A PEGylated fibrin patch was used to de-
liver the chemokine stromal cell–derived factor-1 alpha to
ventricular infarct areas of mice.21 Transmural atrial gene
transfer in pigs was achieved by means of epicardial release
of adenoviral vectors from a poloxamer gel.22 Growth fac-
tor–supplemented collagen matrices enhanced survival of
transplanted cardiomyoblasts in ischemic rat hearts.23 These
examples show the versatility of polymeric release systems,
enabling advances in cardiovascular drug therapy, gene ther-
apy, and cell therapy.24
Limitations
One important difference with human subjects is that the
caprine atrial action potential is shorter.25 In addition, the
atrial structure of patients with cardiovascular disease is
likely to be different from the atrial structure of healthy
goats. Therefore extrapolating the results of the present
study to human subjects must be done with caution.
The follow-up period for this study lasted 28 days after
patch application. Although this period is sufficiently long
lasting for prevention of POAF, it would be interesting to
study drug distribution and electrophysiologic effects for
even longer periods. Patches capable of sustained delivery
of amiodarone for several months might also be used in
the treatment of paroxysmal atrial fibrillation. Minimally
invasive access to the normal pericardial cavity might
further promote the clinical applicability of epicardial poly-
meric release systems.
Animals in the present study did not experience sustained
episodes of atrial fibrillation. Additional studies in represen-
tative animal models are required to evaluate the efficacy of
local amiodarone delivery in the treatment of chronic atrial
fibrillation. Epicardial and endocardial electrophysiologic
mapping might provide further insight into antiarrhythmic
mechanisms of epicardial amiodarone delivery.
Patches were applied only to the RA to evaluate the feasi-
bility of sustained targeted drug delivery to a specific heart
chamber. The RA was chosen to determine the negativerdiovascular Surgery c Volume 140, Number 4 909
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node. R-R intervals briefly increased after patch application,
but no significant sinus bradycardia was observed. In future
clinical application, patches should be applied to both the
RA and LA.
Epicardially placed PEG-based biomaterials are currently
used for prevention of pericardial adhesions after cardiac
surgery.16 However, individual hypersensitivity to amiodar-
one, iodine, or patch degradation products might cause local
inflammation and fibrosis after patch application. Further
studies are needed to evaluate the safety of this method.
The drug-loaded matrix showed minimal adhesive prop-
erties, necessitating suturing of the patch to the atrial epicar-
dium. Future development of a self-adhesive patch by
tailoring PEG matrix characteristics could ease application
and prevent needle-induced microtrauma to the atrium.
CONCLUSIONS
Atrium-targeted delivery of amiodarone is feasible through
epicardial application of a bilayeredpatchwith anamiodarone-
loaded matrix facing the epicardium and an impermeable
backing layer facing the pericardium. Sustained atrial antiar-
rhythmic effects up to 1 month after patch application can be
achieved, whereas tissue drug concentrations in ventricles
and extracardiac tissues remain several orders of magnitude
lower than atrial drug levels. These results indicate that this
method might be promising to prevent POAF with a lower
risk for ventricular and systemic side effects compared with
intravenous and oral amiodarone administration.
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